The fetal placental hypothalamic-pituitary-adrenal (HPA) axis, parturition and post natal health

J. R.G. Challis, D. Sloboda, S. G. Matthews, A. Holloway, N. Alfaidy, F. A. Patel, W. Whittle, M. Fraser, T. J.M. Moss, J. Newnham

Research output: Contribution to journalArticleResearchpeer-review

213 Citations (Scopus)

Abstract

A general characteristic of fetal endocrine maturation across different species is the enhanced activity of the fetal hypothalamic-pituitary-adrenal (HPA) axis during late gestation. Precocious activation of this axis may occur when the fetus is exposed to an adverse intra-uterine environment, such as hypoxemia. HPA development is associated with increased levels of ACTH1-39 and adrenal corticosteroids (cortisol in sheep and human) in the fetal circulation, and increased expression of mRNA encoding corticotrophin releasing hormone (CRH) in the hypothalamus, proopiomelanocortin (POMC) in the pituitary, and key steroidogenic enzymes in the fetal adrenal. At term, increased levels of cortisol act on the placenta/trophoblast derived cells to increase expression of prostaglandin synthase Type II (PGHS-II). In human gestation, cortisol also decreases expression of 15-hydroxyprostaglandin dehydrogenase (PGDH) in chorionic trophoblast cells. Increased synthesis and decreased metabolism of prostaglandin (PG) results, during late gestation, in enhanced output of primary PG, which in turn increases the activity of 11β-hydroxysteroid dehydrogenase (11β HSD) in the human fetal membranes. Increased chorionic 11β HSD-1 results in increased local generation of cortisol from cortisone, with further paracrine/autocrine stimulation of PG output. Increased fetal cortisol contributes to the maturation of organ systems required for postnatal extra-uterine survival. However, excessive levels of feto-placental glucocorticoid, derived from maternal administration of synthetic corticosteroids or sustained endogenous fetal cortisol production, results in intrauterine growth restriction. Fetal sheep, exposed to maternal betamethasone in late gestation, develop insulin resistance and exaggerated adrenal responses to HPA stimulation by 6-12 months postnatal life. Thus, the level of fetal HPA activity is crucial not only for determining gestation length, but may also predict pathophysiologic adjustments in later life.

Original languageEnglish
Pages (from-to)135-144
Number of pages10
JournalMolecular and Cellular Endocrinology
Volume185
Issue number1-2
DOIs
Publication statusPublished - 20 Dec 2001
Externally publishedYes

Keywords

  • Corticotrophin releasing hormone (CRH)
  • Hypothalamic-pituitary-adrenal axis (HPA)
  • Proopiomelanocortin (POMC)

Cite this